GxP Quality & Regulatory Audit Services for Clinical Development and GMP Operations
In today’s stringent global regulatory environment, achieving and maintaining GxP compliance is critical for safeguarding product quality, patient safety, and market readiness. Techsol Life Sciences is a trusted partner for GxP Quality Management and Regulatory Audit Support, helping pharmaceutical, biotech, and medical device companies meet and exceed regulatory expectations across the clinical development and manufacturing value chain.
With over 15 years of global experience across U.S. FDA, EMA, MHRA, Health Canada, PMDA, and WHO regulatory frameworks, we provide end-to-end GxP audit services to ensure inspection readiness, risk mitigation, and lifecycle compliance.
Our Specialized GxP Audit Services
Techsol’s Specialized GxP Audit Services provide comprehensive compliance and quality oversight to ensure product quality, patient safety, and regulatory readiness. Our expertise includes Clinical Development Quality and GCP Compliance Audits, covering investigator sites, vendors, CROs, and trial processes to ensure GCP adherence and inspection readiness. We conduct GMP Compliance and Manufacturing Quality Audits to assess facilities, quality systems, and supply chain partners for global GMP alignment. In addition, our Integrated GxP Quality Management and Regulatory Audit Support includes cross-functional oversight, mock inspections, and end-to-end audit preparation to meet US FDA, EMA, MHRA, PMDA, and other international regulatory expectations.
We help sponsors and CROs maintain ICH-GCP compliance and inspection readiness across all phases of clinical development:
- Clinical Trial Site Audits (Investigator Sites, Hospitals, and Study Centers)
- Sponsor/CRO System Audits & Vendor Qualification Audits
- Pharmacovigilance System Audits (GVP Compliance)
- Clinical Trial Master File (TMF) and Data Integrity Audits
- Inspection Readiness Programs for USFDA, EMA, and MHRA
Key Outcome: Identify gaps, strengthen data integrity, and ensure regulatory compliance for clinical programs.
Techsol provides comprehensive GMP audit services that align with 21 CFR Parts 210/211, EU GMP, WHO TRS, and ICH Q10 principles to maintain manufacturing and product release compliance:
- API, Drug Product, and Biologics Manufacturing Facility Audits
- Contract Manufacturing Organization (CMO) and Contract Testing Laboratory (CTL) Audits
- Quality Management System (QMS) Gap Assessments
- Data Integrity, Cleaning Validation, and Equipment Qualification Reviews
- Pre-Approval Inspection (PAI) Readiness and CAPA Effectiveness Verification
Key Outcome: Ensure global supply chain reliability and regulatory approval readiness for commercial and clinical production.
We provide end-to-end audit lifecycle support, from planning and vendor qualification to regulatory inspection preparedness:
- Development of Risk-Based Audit Programs (RBAP) aligned with ICH Q9 (R1) risk management principles
- Mock Inspections & Gap Assessments to mitigate compliance risks proactively
- CAPA Design and Effectiveness Verification for FDA, EMA, and MHRA audit findings
- Digital Quality Metrics and KPIs for continuous improvement and regulatory intelligence monitoring
- Training and Awareness Programs for internal and external stakeholders
Key Outcome: Achieve sustained inspection readiness, regulatory confidence, and faster time-to-market.

Value Proposition
- Global Regulatory Expertise: Hands-on experience with multi-agency inspections and evolving regulatory expectations.
- End-to-End Audit Solutions: Covering clinical development, manufacturing, pharmacovigilance, and supply chain operations.
- Risk-Based & Digital-Driven Approach: Leverage industry 4.0 tools, data analytics, and quality metrics to reduce compliance risks.
- Proven Track Record: Supported first-in-class therapies, biologics, and complex generics through successful FDA, EMA, and WHO inspections.


Latest Regulatory Trends we consider for various GxP Audit services.
- ICH E6(R3) and E8(R1) for clinical trials emphasizing quality by design and patient safety
- FDA & EMA Data Integrity Guidance for electronic records and system audits
- ICH Q9(R1) Risk Management for proactive GxP audit planning
- ISO 9001 & ISO 13485 Integration for medical devices and combination products
- Remote and Hybrid Audit Models in line with post-pandemic regulatory practices
Regulatory Affairs Services
Latest Relevant Case Studies

May 1, 2025
Specialized Regulatory Writing Solutions for Clinical Overviews in Combination Therapy Submissions

April 29, 2025
Developing a complex clinical trial Protocol for a CNS-based Psychiatric product …

June 10, 2025
Case study on regulatory strategy development and dossier submission support
Latest Relevant Insights

July 12, 2023
Mastering Medical Device Registrations: A Guide to Navigating Regulatory Pathways

June 21, 2021
Evolution in Global Pharmaceutical Regulatory Landscape & Notable Changes for Sponsors

June 5, 2021
Emerging Trends in Regulatory Affairs by Adapting to Latest Technological Advancements